NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 284 filers reported holding NEKTAR THERAPEUTICS in Q4 2019. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $146,493 | +56.7% | 245,958 | +51.3% | 0.00% | – |
| Q2 2023 | $93,504 | -8.5% | 162,559 | +11.8% | 0.00% | – |
| Q1 2023 | $102,198 | -22.8% | 145,395 | +148.1% | 0.00% | – |
| Q4 2022 | $132,450 | -100.0% | 58,606 | -41.9% | 0.00% | -100.0% |
| Q3 2022 | $323,002,000 | -73.0% | 100,938 | -67.9% | 0.00% | -50.0% |
| Q2 2022 | $1,194,705,000 | -8.0% | 314,396 | +30.5% | 0.00% | 0.0% |
| Q1 2022 | $1,298,160,000 | -24.8% | 240,846 | +88.5% | 0.00% | 0.0% |
| Q4 2021 | $1,725,875,000 | +30.7% | 127,748 | +73.8% | 0.00% | 0.0% |
| Q3 2021 | $1,320,132,000 | -36.8% | 73,504 | +6.1% | 0.00% | -33.3% |
| Q2 2021 | $2,088,698,000 | +47.3% | 69,249 | -2.3% | 0.00% | +50.0% |
| Q1 2021 | $1,417,680,000 | +23.5% | 70,884 | +5.0% | 0.00% | 0.0% |
| Q4 2020 | $1,147,534,000 | +33.4% | 67,502 | +30.2% | 0.00% | +100.0% |
| Q3 2020 | $860,208,000 | -31.0% | 51,851 | -3.7% | 0.00% | -50.0% |
| Q2 2020 | $1,247,212,000 | -72.1% | 53,852 | -78.5% | 0.00% | -77.8% |
| Q1 2020 | $4,467,373,000 | -35.0% | 250,273 | -21.4% | 0.01% | -30.8% |
| Q4 2019 | $6,872,124,000 | +260.3% | 318,375 | +204.1% | 0.01% | +333.3% |
| Q3 2019 | $1,907,183,000 | -29.0% | 104,704 | +38.7% | 0.00% | -40.0% |
| Q2 2019 | $2,685,009,000 | +1.2% | 75,464 | -4.5% | 0.01% | -16.7% |
| Q1 2019 | $2,654,232,000 | +38.1% | 78,995 | +35.1% | 0.01% | +20.0% |
| Q4 2018 | $1,921,876,000 | -72.5% | 58,469 | -48.9% | 0.01% | -50.0% |
| Q3 2018 | $6,980,408,000 | -25.9% | 114,508 | -40.6% | 0.01% | -37.5% |
| Q2 2018 | $9,414,619,000 | +53.9% | 192,804 | +234.9% | 0.02% | +45.5% |
| Q1 2018 | $6,117,282,000 | +11.0% | 57,569 | -37.6% | 0.01% | +10.0% |
| Q4 2017 | $5,512,574,000 | +104.0% | 92,307 | -18.0% | 0.01% | +42.9% |
| Q3 2017 | $2,702,016,000 | +69.4% | 112,584 | +38.0% | 0.01% | +40.0% |
| Q2 2017 | $1,595,260,000 | -11.9% | 81,599 | +5.7% | 0.01% | 0.0% |
| Q1 2017 | $1,811,532,000 | +115.1% | 77,185 | +12.4% | 0.01% | +25.0% |
| Q4 2016 | $842,336,000 | -17.0% | 68,650 | +16.3% | 0.00% | 0.0% |
| Q3 2016 | $1,014,324,000 | -12.0% | 59,041 | -27.1% | 0.00% | -20.0% |
| Q2 2016 | $1,152,089,000 | +36.5% | 80,962 | +31.9% | 0.01% | +25.0% |
| Q1 2016 | $843,741,000 | -65.3% | 61,363 | -57.4% | 0.00% | -33.3% |
| Q4 2015 | $2,429,770,000 | +135.3% | 144,200 | +53.0% | 0.01% | +100.0% |
| Q3 2015 | $1,032,761,000 | +8.9% | 94,230 | +24.3% | 0.00% | 0.0% |
| Q2 2015 | $948,633,000 | +1477.2% | 75,830 | +1286.8% | 0.00% | – |
| Q1 2015 | $60,148,000 | +77.5% | 5,468 | +150.1% | 0.00% | – |
| Q4 2014 | $33,883,000 | -64.4% | 2,186 | -72.3% | 0.00% | – |
| Q3 2014 | $95,220,000 | +5166.6% | 7,889 | +5495.0% | 0.00% | – |
| Q2 2014 | $1,808,000 | -2.8% | 141 | -10.8% | 0.00% | – |
| Q1 2014 | $1,860,000 | -89.1% | 158 | -89.5% | 0.00% | – |
| Q4 2013 | $17,002,000 | -94.9% | 1,498 | -95.3% | 0.00% | – |
| Q3 2013 | $332,169,000 | -28.6% | 31,817 | -21.1% | 0.00% | – |
| Q2 2013 | $465,546,000 | – | 40,307 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |